NCT06727227 - Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Breast Cancer

Interventions

DRUG

trastuzumab deruxtecan

T-DXd

Trial Locations (14)

1000

RECRUITING

Research Site, Ljubljana

1303

ACTIVE_NOT_RECRUITING

Research Site, Sofia

1330

ACTIVE_NOT_RECRUITING

Research Site, Sofia

1407

NOT_YET_RECRUITING

Research Site, Sofia

1431

ACTIVE_NOT_RECRUITING

Research Site, Sofia

1527

ACTIVE_NOT_RECRUITING

Research Site, Sofia

1618

NOT_YET_RECRUITING

Research Site, Sofia

1756

ACTIVE_NOT_RECRUITING

Research Site, Sofia

2000

RECRUITING

Research Site, Maribor

4004

NOT_YET_RECRUITING

Research Site, Plovdiv

4500

NOT_YET_RECRUITING

Research Site, Panagyurishte

6003

NOT_YET_RECRUITING

Research Site, Stara Zagora

8000

RECRUITING

Research Site, Burgas

9003

ACTIVE_NOT_RECRUITING

Research Site, Varna